In setting the panel for the Sarepta gene therapy meeting, the US FDA has called on experts from prior muscular dystrophy drug reviews. • Source: Shutterstock
Learn what's happening at the US FDA. On the go.
Derrick Gingery and the team bring you a weekly "Drug Fix".
